ZEBIAI
ZebiAI is a platform that applies massive experimental DNA encoded library data sets to power machine learning for drug discovery.ZebiAI Therapeutics is focused on applying machine learning (ML) at all stages of small molecule drug discovery to accelerate target validation and advance new therapeutics for unmet medical needs.
ZEBIAI
Industry:
Artificial Intelligence Biotechnology Health Care Machine Learning Pharmaceutical
Founded:
2019-01-01
Address:
Waltham, Massachusetts, United States
Country:
United States
Website Url:
http://www.zebiai.com
Status:
Active
Technology used in webpage:
SPF Microsoft Exchange Online Amazon Office 365 Mail Microsoft Azure DNS GoDaddy DNS COVID-19 Amazon S3 CDN Mimecast
Similar Organizations
EntheogeniX Biosciences
Using AI and computational biophysics to uncover new medicines from desired psychedelics.
EpiVax
EpiVax is an immunology company developing comprehensive analytical capabilities in the field of computational immunology.
Founder
Key Employee Changes
| Date | New article |
|---|---|
| 2021-02-09 | ZebiAI Announces Appointment of Brian Goldman, Ph.D. as SVP and Chief Computation Scientist |
Official Site Inspections
http://www.zebiai.com
- Host name: ec2-107-22-225-163.compute-1.amazonaws.com
- IP address: 107.22.225.163
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "ZebiAI" on Search Engine
ZebiAI - Crunchbase Company Profile & Funding
Operating Status Active. Also Known As ZebiAI Therapeutics. Company Type For Profit. ZebiAI is a platform that applies massive experimental DNA encoded library data sets to power machine learning for drug discovery.ZebiAI Therapeutics is focused on applying machine learning (ML) at all stages of small molecule drug discovery to accelerate ...See details»
Relay buys AI startup to aid unorthodox drug discovery …
Apr 16, 2021 Dive Brief: Relay Therapeutics, a five-year-old biotech developing targeted cancer medicines, has acquired ZebiAI, a startup launched in 2019 to develop machine learning tools for drug discovery, the companies announced Friday . Relay will pay $85 million upfront for ZebiAI, split between $20 million in cash and $65 million in Relay shares.See details»
ZebiAI Company Profile 2024: Valuation, Investors, …
General Information. Description. Developer of a genome technology intended to apply machine learning at all stages of small molecule drug discovery. The company's technology applies machine learning …See details»
Relay Therapeutics Acquires ZebiAI, Extends …
April 16, 2021. CAMBRIDGE, Mass., April 16, 2021 -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company combining leading edge computational and experimental technologies for drug discovery, today announced the acquisition of ZebiAI, a pioneer in applying massive experimental DNA encoded library data sets to ...See details»
Relay Therapeutics Extends Leadership in Integrating
Apr 16, 2021 ZebiAI builds on Relay Therapeutics’ approach by bringing a massive library of curated experimental data, validated machine learning models, a collaboration with Google’s Accelerated Science...See details»
ZebiAI Company Profile - Office Locations, Competitors, …
Company Summary. ZebiAI Therapeutics is a drug discovery company. Its technology applies ML and AI algorithms to protein-small molecule interaction data from DNA-encoded library (DEL) screens to accelerate target validation by providing tool compounds to the research community, and discover and optimize chemical matter into clinical candidates.See details»
Relay Therapeutics Inks $85M Deal To Buy ZebiAI
Apr 16, 2021 Relay Therapeutics, a clinical-stage precision medicine company announced the acquisition of ZebiAI, a pioneer in applying massive experimental DNA encoded library data sets to power machine...See details»
Relay Therapeutics Inks $85M Deal To Buy ZebiAI - Yahoo Finance
Apr 16, 2021 RLAY. Relay Therapeutics, a clinical-stage precision medicine company announced the acquisition of ZebiAI, a pioneer in applying massive experimental DNA encoded library data sets to power...See details»
Relay Therapeutics Acquires ZebiAI | citybiz
Apr 16, 2021 ZebiAI builds on Relay Therapeutics’ approach by bringing a massive library of curated experimental data, validated machine learning models, a collaboration with Google’s Accelerated Science Group to …See details»
Relay Therapeutics acquires ZebiAI - 2021-04-16
Apr 16, 2021 Overview. Acquired Organization: ZebiAI ZebiAI is a platform that applies massive experimental DNA encoded library data sets to power machine learning for drug discovery. Acquiring Organization: Relay Therapeutics Relay therapeutics is a developer of an allosteric drug-discovery platform intended to apply computational techniques to …See details»
Relay Therapeutics Acquires ZebiAI for $85 Million Upfront
Apr 28, 2021 Share. The Life Sciences team advised Relay Therapeutics, Inc. (Nasdaq: RLAY) on its acquisition of ZebiAI. Relay Therapeutics is a clinical-stage precision medicine company transforming the drug discovery process by combining leading edge computational, and experimental technologies.See details»
ZebiAI and TB Alliance Announce Collaboration to Apply ML …
Feb 1, 2021 WALTHAM, Mass.-- ( BUSINESS WIRE )--ZebiAI, Inc., a biotech company focused on improving human health by powering machine learning (ML) to source novel targets and discover new therapeutics,...See details»
ZebiAI Joins the EUbOPEN Consortium to Provide Tools to …
Nov 5, 2020 ZebiAI Therapeutics is a privately held biotechnology company based in Waltham, Massachusetts, focused on improving human health by powering machine learning (ML) to map the chemistry of the...See details»
ZebiAI and TB Alliance Announce Collaboration to Apply ML …
February 1, 2021. WALTHAM, Mass., February 1, 2021 – ZebiAI, Inc., a biotech company focused on improving human health by powering machine learning (ML) to source novel targets and discover new therapeutics, today announced a strategic collaboration agreement with TB Alliance, a not-for-profit organization dedicated to the discovery ...See details»
ZebiAI and TB Alliance Announce Collaboration to Apply ML …
Feb 1, 2021 WALTHAM, Mass.--(BUSINESS WIRE)--ZebiAI, Inc., a biotech company focused on improving human health by powering machine learning (ML) to source novel targets and discover new therapeutics, today announced a strategic collaboration agreement with TB Alliance, a not-for-profit organization dedicated to the discovery, development …See details»
ZebiAI Therapeutics, Inc. Announces Collaboration With Google ...
Jan 13, 2020 ZebiAI Therapeutics, Inc. Announces Collaboration With Google Accelerated Science to Focus on Unlocking Novel Therapeutic Targets and Transforming Small Molecule Drug Discovery | Business Wire.See details»
ZebiAI Therapeutics, Inc. and X-Chem Enter into Strategic …
Jan 13, 2020 ZebiAI Therapeutics, Inc. is a newly established company, founded by X-Chem co-founder and CEO Richard Wagner, Ph.D., focused on the application of machine learning technologies to the discovery of chemical probes for researchers in academia and industry and on the exploration of artificial intelligence to accelerate discovery of clinical …See details»
ZebiAI - Contacts, Employees, Board Members, Advisors
ZebiAI is a platform that applies massive experimental DNA encoded library data sets to power machine learning for drug discovery.See details»
ZebiAI and TB Alliance Announce Collaboration to Apply ML
Feb 1, 2021 WALTHAM, Mass.-- ( BUSINESS WIRE )-- ZebiAI, Inc., a biotech company focused on improving human health by powering machine learning (ML) to source novel targets and discover new therapeutics, today announced a strategic collaboration agreement with TB Alliance, a not-for-profit organization dedicated to the discovery, development …See details»
ZebiAI Therapeutics, Inc. and X-Chem Enter into Strategic …
Jan 13, 2020 ZebiAI Therapeutics, Inc. is a newly established company, founded by X-Chem co-founder and CEO Richard Wagner, Ph.D., focused on the application of machine learning technologies to the discovery...See details»